Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026
Go back to Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026| (NASDAQ: VYGR) | Delayed: 3.04 -0.01 (0.33%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.05 | 52 Week High | $30.54 | |||
| Open | $3.05 | 52 Week Low | $8.12 | |||
| Day High | $3.11 | P/E | N/A | |||
| Day Low | $3.00 | EPS | $0.00 | |||
| Volume | 681,164 | |||||
